Genelux Corporation
$2.65
▲
0.39%
2026-04-21 07:07:01
www.genelux.com
NCM: GNLX
Explore Genelux Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$125.01 M
Current Price
$2.65
52W High / Low
$8.54 / $2.25
Stock P/E
—
Book Value
$0.31
Dividend Yield
—
ROCE
-259.44%
ROE
-1.7%
Face Value
—
EPS
$-0.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
25
Beta
0.46
Debt / Equity
14.6
Current Ratio
2.43
Quick Ratio
2.43
Forward P/E
-3.09
Price / Sales
14,225.84
Enterprise Value
$99.8 M
EV / EBITDA
-3.03
EV / Revenue
12,474.51
Rating
None
Target Price
$17.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Avalo Therapeutics, Inc. | $14.66 | — | $334.08 M | — | -70.45% | -72.44% | $20.72 / $3.39 | $4.49 |
| 2. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 3. | Candel Therapeutics, Inc. | $7.22 | — | $466.58 M | — | -41.46% | -64.58% | $7.25 / $4.34 | $0.95 |
| 4. | Solid Biosciences Inc. | $8.49 | — | $835.34 M | — | -90.02% | -1.1% | $8.87 / $2.41 | $2.28 |
| 5. | Kairos Pharma, Ltd. | $0.63 | — | $13.1 M | — | -87.87% | -97.99% | $2.11 / $0.4 | $0.37 |
| 6. | Ardelyx, Inc. | $6.3 | — | $1.59 B | — | -9.92% | -36.21% | $8.4 / $3.21 | $0.68 |
| 7. | Immix Biopharma, Inc. | $10.09 | — | $548.68 M | — | -31.62% | -55% | $11.61 / $1.57 | $1.77 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.01 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -9.41 M | -8.19 M | -7.79 M | -7.82 M | -9.75 M | — |
| Net Profit | -9.25 M | -7.95 M | -7.46 M | -7.49 M | -8.98 M | — |
| EPS in Rs | -0.21 | -0.18 | -0.17 | -0.17 | -0.2 | -0.19 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.01 M | 0.01 M | 0.17 M | 11.07 M |
| Operating Profit | -33.21 M | -31.7 M | -24.16 M | -3.01 M |
| Net Profit | -32.15 M | -29.87 M | -28.3 M | -5.21 M |
| EPS in Rs | -0.72 | -0.67 | -0.63 | -0.12 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 19.03 M | 34.72 M | 27.89 M | 5.53 M |
| Total Liabilities | 7.48 M | 8.44 M | 8.42 M | 41.31 M |
| Equity | 11.54 M | 26.27 M | 19.47 M | -35.78 M |
| Current Assets | 15.13 M | 31.55 M | 24.2 M | 1.89 M |
| Current Liabilities | 6.22 M | 6.9 M | 6.55 M | 31.63 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -25.27 M | -21.23 M | -20.27 M | -3.57 M |
| Investing CF | 12.14 M | -8.13 M | -14.72 M | -0.05 M |
| Financing CF | 9.89 M | 28.51 M | 44.02 M | -0.48 M |
| Free CF | -26.37 M | -21.61 M | -21.3 M | -3.62 M |
| Capex | -1.1 M | -0.38 M | -1.02 M | -0.05 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -95.29% | -98.46% | — | — |
| Earnings Growth % | -5.56% | -443.44% | — | — |
| Profit Margin % | -373362.5% | -16645.29% | -47.05% | — |
| Operating Margin % | -396200% | -14214.71% | -27.22% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -384912.5% | -15562.94% | -15.64% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.